Solventum Corporation (NYSE:SOLV) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Solventum Corporation (NYSE:SOLV) have been given a consensus rating of “Hold” by the fourteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $88.6364.

Several research analysts have commented on SOLV shares. BTIG Research raised Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Tuesday, December 2nd. UBS Group reaffirmed a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Stifel Nicolaus upped their price target on shares of Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Wall Street Zen upgraded shares of Solventum from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. United Services Automobile Association acquired a new stake in shares of Solventum during the first quarter worth $239,000. Woodline Partners LP raised its position in Solventum by 40.7% during the 1st quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after buying an additional 3,377 shares during the last quarter. Intech Investment Management LLC lifted its stake in shares of Solventum by 167.0% in the 1st quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock worth $1,268,000 after acquiring an additional 10,425 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Solventum by 0.7% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company’s stock valued at $1,500,000 after acquiring an additional 140 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of Solventum by 5.0% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 47,894 shares of the company’s stock worth $3,760,000 after acquiring an additional 2,281 shares during the period.

Solventum Price Performance

Shares of NYSE:SOLV opened at $79.59 on Tuesday. Solventum has a 12 month low of $60.70 and a 12 month high of $88.20. The firm has a market capitalization of $13.80 billion, a P/E ratio of 9.17, a P/E/G ratio of 7.91 and a beta of 0.34. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The company’s fifty day moving average price is $81.25 and its 200 day moving average price is $75.62.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.07. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The company had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. During the same quarter last year, the company posted $1.64 earnings per share. The business’s quarterly revenue was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, sell-side analysts predict that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its board has approved a stock buyback plan on Thursday, November 20th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to purchase up to 7.5% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its shares are undervalued.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.